Continuation of the NuMoM2b Heart Health Study

项目摘要/摘要 不良妊娠结局和并发症，如早产、先兆子痫、 胎儿宫内发育受限和妊娠期糖尿病对孕妇构成重大风险。 对这些妊娠结局的最强预测因素是妊娠结局在 然而，这给人们在风险预测方面留下了很大的知识缺口 他们的第一次怀孕(未产妇)。为了解决这一差距，未分娩妊娠结局研究： 监测准妈妈(NuMoM2B)登记和丰富的表型人口统计学多样性 第一次怀孕的妇女的队列。该队列的高质量数据和生物样本是 在支持资源共享和数据汇编的监管框架下收集 在未来的研究中使用。即将公开发布的nuMoM2B生物样品需要 使用NICHD提供的模板化电子表格汇总生物样品元数据，该电子表格 将由RTI的nuMoM2B心脏健康研究团队完成。提供给NICHD的数据 将包括项目数据中可用的所有请求字段。这些数据将提供给 最初在nuMoM2B期间收集但尚未分析或 用于分析和一组等分的母体和胎儿DNA，这些DNA是从 NuMoM2B标本。具体的目标反映了一种实现优势的有效方法 生物素汇编，可用于未来的分析。RTI团队将收到 来自跟踪nuMoM2B生物胺使用情况的网络伙伴提供的最新生物胺清单 (目标1)。一旦RTI收到信息，nuMoM2B心脏健康研究团队将运行质量 对照库存文件进行控制检查，以确保信息的准确性，然后将其合并 使用nuMoM2B数据(目标2)。合并后，数据将在可用中导出 所请求格式的生态元数据字段(目标3)。在整个过程中，团队将 还为支持这项工作的资金管理提供支助。拥有强大的基础 领导能力和技术基础设施，RTI将为汇编nuMoM2B提供理想的环境 数据，以继续填补该领域的关键知识差距。

PROJECT SUMMARY/ABSTRACT Adverse pregnancy outcomes and complications such as preterm birth, preeclampsia, intrauterine growth restriction, and gestational diabetes present significant risks to pregnant people. The strongest predictor of these pregnancy outcomes is the occurrence of the outcome during a prior pregnancy; however, this leaves a large knowledge gap regarding risk prediction for people in their first pregnancy (nulliparas). To address this gap, the Nulliparous Pregnancy Outcomes Study: Monitoring Mothers-to-Be (nuMoM2b) enrolled and richly phenotyped a demographically diverse cohort of women during their first pregnancy. The cohort’s high-quality data and biospecimens were collected under regulatory frameworks that support resource sharing and data compilation leading to use in future research. The upcoming public release of nuMoM2b biospecimens requires the aggregation of biospecimen metadata using a templated spreadsheet provided by NICHD, which will be completed by the nuMoM2b Heart Health Study team at RTI. The data provided to NICHD will include all requested fields available in the project data. These data will be provided for the biospecimens that were originally collected during nuMoM2b and have not yet been analyzed or earmarked for analysis and a set of aliquots of maternal and fetal DNA that were derived from nuMoM2b specimens. The Specific Aims reflect an efficient approach to completing advantageous biospecimen compilation, which can be used in analyses going forward. The RTI team will receive updated biospecimen inventories from the network partners tracking nuMoM2b biospecimen use (Aim 1). Once RTI receives information, the nuMoM2b Heart Health Study team will run quality control checks against the inventory files to ensure accuracy of information and then merge them with the nuMoM2b data (Aim 2). Upon merging, data will then be exported in the available biospecimen metadata fields in the requested format (Aim 3). Throughout the process, the team will also provide support for administration of the funds to support this work. With a foundation of strong leadership and technical infrastructure, RTI will provide an ideal setting for compiling nuMoM2b data to continue addressing critical knowledge gaps in the field.